References
- 1. Björnsson E.S. (2016) Hepatotoxicity by Drugs: The Most Common Implicated Agents. Int. J. Mol. Sci., 17(2): 224.
- 2. Lee W.M. (2003) Drug-induced hepatotoxicity. N. Engl. J. Med., 349(5): 474–485.
- 3. Iasella C.J., Johnson H.J., Dunn M.A. (2017) Adverse Drug Reactions: Type A (Intrinsic) or Type B (Idiosyncratic). Clin. Liver Dis., 21(1): 73–87.
- 4. Shehu A.I., Ma X., Venkataramanan R. (2017) Mechanisms of Drug-Induced Hepatotoxicity. Clin. Liver Dis., 21(1): 35–54.
- 5. Xu Y., Yao H., Wang Q. et al. (2018) Aquaporin-3 Attenuates Oxidative Stress-Induced Nucleus Pulposus Cell Apoptosis Through Regulating the P38 MAPK Pathway. Cell Physiol. Biochem., 50: 1687–1697.
- 6. Wang R., Deng D., Shao N. et al. (2018) Evodiamine activates cellular apoptosis through suppressing PI3K/AKT and activating MAPK in glioma. OncoTargets Ther., 11: 1183–1192.
- 7. Pessayre D., Mansouri A., Berson A., Fromenty B. (2009) Mitochondrial Involvement in Drug-Induced Liver Injury. Adverse Drug Reactions, pp. 311–365.
- 8. Mihajlovic M., Vinken M. (2022) Mitochondria as the Target of Hepatotoxicity and Drug-Induced Liver Injury: Molecular Mechanisms and Detection Methods. Int. J. Mol. Sci., 23(6): 3315.
- 9. Prasanna P.L., Renu K., Gopalakrishnan A.V. (2020) New molecular and biochemical insights of doxorubicin-induced hepatotoxicity. Life Sci., 250: 117599.
- 10. Nam J., Son S., Ochyl L.J. et al. (2018) Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer. Nat. Commun., 9: 1074.
- 11. Roychoudhury S., Kumar A., Bhatkar D., Sharma N.K. (2020) Molecular avenues in targeted doxorubicin cancer therapy. Future Oncol., 16: 687–700.
- 12. Braicu C., Buse M., Busuioc C. et al. (2019) A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer. Cancers, 11: 1618.
- 13. Pfitzer L., Moser C., Gegenfurtner F. et al. (2019) Targeting actin inhibits repair of doxorubicin-induced DNA damage: A novel therapeutic approach for combination therapy. Cell Death Dis., 10: 302.
- 14. Songbo M., Lang H., Xinyong C. et al. (2019) Oxidative stress injury in doxorubicin-induced cardiotoxicity. Toxicol. Lett., 307: 41–48.
- 15. Mansouri E., Jangaran A., Ashtari A. (2017) Protective effect of pravastatin on doxorubicin-induced hepatotoxicity. Bratisl. Lek. Listy, 118: 273–277.
- 16. Lamas D.J.M., Nicoud M.B., Sterle H.A. et al. (2015) Selective cytoprotective effect of histamine on doxorubicin-induced hepatic and cardiac toxicity in animal models. Cell Death Discov., 1: 15059.
- 17. AlAsmari A.F., Alharbi M., Alqahtani F. et al. (2021) Diosmin Alleviates Doxorubicin-Induced Liver Injury via Modulation of Oxidative Stress-Mediated Hepatic Inflammation and Apoptosis via NfkB and MAPK Pathway: A Preclinical Study. Antioxidants (Basel), 10(12): 1998. doi: 10.3390/antiox10121998.
- 18. Oliva J., Zhong J., Buslon V.S., French S.W. (2012) The effect of SAMe and betaine on Hepa 1-6, C34 and E47 liver cell survival in vitro. Exp. Mol. Pathol., 92(1): 126–130.
- 19. Chen Y., Dong H., Thompson D.C., Shertzer H.G. (2013) Glutathione defense mechanism in liver injury: insights from animal models. Food Chem. Toxicol., 60: 38–44.
- 20. Смоланка І.І., Скляр С.Ю., Іванкова О.М., Костриба О.І. (2013) Ефективність неоад’ювантної поліхіміотерапії у хворих на рак грудної залози. Лікувальний патоморфоз. Клінічна онкологія, 2(10): 63–68.